Sugi Predict

Sugi Predict / Compounds / SCHEMBL857551

SCHEMBL857551

SCHEMBL857551

O[C@@H]1[C@H](O)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 2/20 0.59
▸ MTOR P42345 1/20 0.59
▸ BCHE P06276 3/20 0.48
▸ TSHR P16473 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ ACHE P22303 2/20 0.42
▸ GRM2 Q14416 1/20 0.42
▸ GRM3 Q14832 1/20 0.42
▸ SLC6A2 P23975 2/20 0.42
▸ AGXT P21549 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ TACR1 P25103 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13207930 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL11008169 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL19479654 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL13207995 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL1117739 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL6366009 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL31175740 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL9452147 1.00 PDPK1 (0.59) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL9294599 0.98 PDPK1 (0.58) PDPK1MTORBCHETSHRALDH1A1
SCHEMBL6575740 0.98 PDPK1 (0.58) PDPK1MTORBCHETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718757-B1 GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-03-28 — — EP claimed
US-20070111263-A1 GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-17 — — US claimed
EP-1566447-A1 Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation Aventis Pharma Deutschland GmbH (DE) 2005-08-24 — — EP claimed
EP-1718757-B1 GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-03-28 — — EP disclosed
US-8017350-B2 Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-09-13 — — US disclosed
US-7589072-B2 Inositol-based molecular transporters and processes for the preparation thereof POSTECH FOUNDATION (KR) 2009-09-15 — — US disclosed
US-20070129336-A1 Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use INOLOGIC, INC. (US) 2007-06-07 — — US disclosed
US-20070111263-A1 GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-17 — — US disclosed
US-20060280796-A1 Inositol-based molecular transporters and processes for the preparation thereof POSTECH FOUNDATION (KR) 2006-12-14 — — US disclosed
EP-1566447-A1 Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation Aventis Pharma Deutschland GmbH (DE) 2005-08-24 — — EP disclosed
US-6376697-B1 Labelled phosphoinositides and analogues NUTRIMED BIOTECH 2002-04-23 — — US disclosed
US-6221856-B1 Inositol derivatives for inhibiting superoxide anion production INOLOGIC, INC. 2001-04-24 — — US disclosed
US-5693521-A USING ACETOXYALKYL ESTER OF ADENOSINE(OR GUANOSINE)-3',5'-CYCLIC MONNOPHOSPHATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-12-02 — — US disclosed
WO-1994023724-A1 MEMBRANE-PERMEANT SECOND MESSENGERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-10-27 — — WO disclosed
US-4515722-A Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents MERCK & CO., INC. (US) 1985-05-07 — — US disclosed
US-4474806-A Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents MERCK & CO., INC. (US) 1984-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060280796-A1 Inositol-based molecular transporters and processes for the preparation thereof SLC2A8, SLC2A1, SLC29A2 PDPK1 405/4885MTOR 1425/4885BCHE 3011/4885
US-20070129336-A1 Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use ITPR1, ITPA, ITPR3 PDPK1 234/4885MTOR 1777/4885BCHE 1705/4885
US-20070111263-A1 GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION GPR119, GID4, PLD1 PDPK1 269/4885MTOR 4121/4885BCHE 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.